Loading
A phase 1/2 trial of ONO-4538HSC in epithelioid sarcoma, run by Ono Pharmaceutical Co., Ltd., now recruiting.
A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma. is a phase 1/2 interventional study registered as NCT07734116 by Ono Pharmaceutical Co., Ltd., with 50 participants planned, started 2026-08-18 and due to reach its primary completion in 2029-11-30. Interventions recorded: ONO-4538HSC.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Deciphera Pharmaceuticals (Ono) and the tag pipeline.
Shares Deciphera Pharmaceuticals (Ono) and the tag pipeline.
Shares Deciphera Pharmaceuticals (Ono) and the tag pipeline.
Shares Deciphera Pharmaceuticals (Ono) and the tag pipeline.
Shares Deciphera Pharmaceuticals (Ono) and the tag pipeline.
Shares Epithelioid sarcoma and the tag pipeline.
Shares Deciphera Pharmaceuticals (Ono) and the tag pipeline.
Shares Deciphera Pharmaceuticals (Ono) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/